The concept of cancer immunotherapy has become an important component of modern oncology and the therapeutic approaches to fight tumors. The strategies that are mainly followed in order to enhance the antitumor immune responses, are the ones that modulate the immune checkpoint pathways. Among the various agents used as Immunotherapeutics, the class of agents referred to as pd-1 inhibitors, has emerged as therapeutic agents for patients with various types of cancers. As more and more clinical experience is gained, strategies for better patient selection, resistance mechanisms, and combination with other agents, are being investigated at different stages of cancer.
Recent advances in translational research, diagnostics and immunology have expanded the understanding of the signaling pathway of PD-1 and the tumor environment. In view of these recent findings, there are many new aspects, which are currently under investigation and which may also influence future treatment recommendations. The knowledge of these new findings is of importance for health care professionals to be able to interpret current clinical studies and to include recent evidence-based knowledge in their oncological treatment. This article outlines current directions in the research with PD-1 inhibitor and highlights some of the emerging scientific evidence that could influence future clinical practice.
The Expanding Role of PD-1 Inhibitors
Immune checkpoint inhibition is moving from treating selected patients with advanced and often metastasized cancer to investigating its application in a wide spectrum of diseases at various stages of development and in different treatment settings. Current research is evaluating PD-1 inhibitors in:
There is ongoing research into how PD-1 inhibitors can be used properly throughout the cancer treatment process.
Advances in Understanding the Tumor Microenvironment
The tumor microenvironment has emerged as a major area of research into immunotherapy. The interactions between tumor cells and the immune cells in the vicinity, as well as with the surrounding stroma, may influence both immune activation and treatment response. Current investigations are examining:
Understanding the interactions between tumor cells and the immune system can provide insights into why patients respond differently to treatment, and to the development of further anti-tumor therapies. There are ongoing studies on tumor cells, immune cells, and tumor stroma in tumor microenvironments.
Biomarker Research Beyond PD-L1
While PD-L1 remains a relevant biomarker in several clinical situations, no single biomarker predicts response to immunotherapy in all tumor types. Emerging areas of biomarker investigation include:
Future biomarkers will probably consist of a variety of different biological variables to help in selection of patients for specific treatment regimens.
Combination Immunotherapy Strategies
Clinical studies are evaluating combinations with:
The goal of many of the current studies is to combine a PD-1 inhibitor with other agents to improve their antitumor effects and check for toxicity. Work remains to be done to better define optimal sequencing and duration of administration.
Investigating Mechanisms of Resistance
Outcome of PD-1 inhibition may vary among different patients. Most tumors may return, either immediately or following an initial period of response. Current research seeks to better understand:
A better understanding of the resistance mechanisms could lead to the development of new single or combination therapies.
Artificial Intelligence and Precision Oncology
Artificial intelligence and computational pathology are increasingly being incorporated into oncology research. Emerging applications include:
These emerging technologies can facilitate identifying complex patterns that are difficult to capture using typical analytical approaches. Future studies will be required to further validate the implementation of these emerging technologies in clinical settings through prospective studies.
Expanding Clinical Trial Design
Clinical trial design is evolving within the frame of research into immunotherapy. Modern oncology trials increasingly incorporate:
New clinical trial designs may help improve the trials’ efficiency to generate meaningful clinical evidence to treat different types of cancer. International collaboration is speeding up enrollment and the generation of data for studies with immunotherapies.
Safety Research and Toxicity Management
As PD-1 inhibitors are increasingly approved for use in different cancers, their toxicities are being more fully characterized. Current investigations focus on:
Early recognition of toxicity allows for treatment intervention while maintaining the treatment’s effectiveness as clinically indicated. Pharmacovigilance studies are on-going to contribute to safety information from different patient populations.
Future Directions in PD-1 Inhibitor Research
Continued advances in cancer immunology are expected to further optimize the use of single agents like PD-1 inhibitors as well as in combination with other cancer therapies in various oncology disciplines. Future research priorities include:
Advances in the fields of molecular biology, immunology, bioinformatics and clinical oncology are expected to provide additional insight into the biology of immune checkpoint proteins and their manipulation for cancer treatment in an increasingly individualized fashion. Healthcare professionals should stay updated on emerging data, clinical guidelines and research methods as Immunotherapy keeps evolving.
Key Takeaways
Research involving the use of the pd-1 inhibitor is rapidly expanding across basic science, translational science and clinical work within the oncology realm. Recent advances in biomarkers, the cancer’s tumor environment, mechanisms of resistance to therapy, combination of different therapies, use of artificial intelligence as well as clinical trial design have contributed significantly to the evolving understanding of immune checkpoint inhibition.
For health care professionals, knowledge of the current research is vital to understand new findings and, in the future, how they may impact patient selection, treatment, toxicities and health care for cancer patients in general and for a number of tumors in particular. Clearly, more work is needed to establish the optimal role of these drugs in different cancers and to support health care based oncology.